4/A//SEC Filing
ANI PHARMACEUTICALS INC 4/A
Accession 0001144204-14-016518
$ANIPCIK 0001023024operating
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 8:51 PM ET
Size
19.4 KB
Accession
0001144204-14-016518
Insider Transaction Report
Form 4/AAmended
MERIDIAN VENTURE PARTNERS II LP
10% Owner
Transactions
- Sale
Common Stock
2014-03-13$33.31/sh−6,752$224,909→ 2,732,021 total - Sale
Common Stock
2014-03-13$32.53/sh−12,138$394,849→ 2,738,773 total - Sale
Common Stock
2014-03-12$33.61/sh−32,802$1,102,475→ 2,786,942 total - Sale
Common Stock
2014-03-12$34.33/sh−2,517$86,409→ 2,784,425 total - Sale
Common Stock
2014-03-13$31.05/sh−33,514$1,040,610→ 2,750,911 total
Transactions
- Sale
Common Stock
2014-03-12$33.61/sh−32,802$1,102,475→ 2,786,942 total - Sale
Common Stock
2014-03-13$31.05/sh−33,514$1,040,610→ 2,750,911 total - Sale
Common Stock
2014-03-13$33.31/sh−6,752$224,909→ 2,732,021 total - Sale
Common Stock
2014-03-13$32.53/sh−12,138$394,849→ 2,738,773 total - Sale
Common Stock
2014-03-12$34.33/sh−2,517$86,409→ 2,784,425 total
Brown Robert E. JR
Director10% Owner
Transactions
- Sale
Common Stock
2014-03-12$34.33/sh−2,517$86,409→ 2,784,425 total - Sale
Common Stock
2014-03-12$33.61/sh−32,802$1,102,475→ 2,786,942 total - Sale
Common Stock
2014-03-13$31.05/sh−33,514$1,040,610→ 2,750,911 total - Sale
Common Stock
2014-03-13$32.53/sh−12,138$394,849→ 2,738,773 total - Sale
Common Stock
2014-03-13$33.31/sh−6,752$224,909→ 2,732,021 total
Meridian Venture Partners II, Co.
10% Owner
Transactions
- Sale
Common Stock
2014-03-12$33.61/sh−32,802$1,102,475→ 2,786,942 total - Sale
Common Stock
2014-03-13$32.53/sh−12,138$394,849→ 2,738,773 total - Sale
Common Stock
2014-03-13$33.31/sh−6,752$224,909→ 2,732,021 total - Sale
Common Stock
2014-03-12$34.33/sh−2,517$86,409→ 2,784,425 total - Sale
Common Stock
2014-03-13$31.05/sh−33,514$1,040,610→ 2,750,911 total
Footnotes (7)
- [F1]On March 14, 2014, the reporting person filed a Form 4 that reported sales of the Issuer's securities, which Form 4 contained an inadvertent error in the amount of securities beneficially owned following the reported sales transaction. This Form 4 also corrects the method of reporting the prices of the securities sold.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.20 to $34.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
- [F3]Meridian Venture Partners II, Co. (MVP Corp.) is the general partner of Meridian Venture Partners II GP, L.P. (GP), the general partner of Meridian Venture Partners II, L.P. (MVP II). Robert E. Brown, Jr., a director of the issuer, is the President, sole stockholder and sole director of MVP Corp., as well as a limited partner of GP and one of two principals of MVP II.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.20 to $34.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.05 to $32.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.20 to $33.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
Documents
Issuer
ANI PHARMACEUTICALS INC
CIK 0001023024
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001023024
Filing Metadata
- Form type
- 4/A
- Filed
- Mar 17, 8:00 PM ET
- Accepted
- Mar 18, 8:51 PM ET
- Size
- 19.4 KB